

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis

Hatem Ali^{1,2}, Atif Mohiuddin^{2,3}, Ajay Sharma^{2,3}, Mohsen El Kosi^{2,4} and Ahmed Halawa^{2,5}

¹Department of Renal Medicine, Royal Wolverhampton Hospitals NHS Foundation Trust, Wolverhampton, UK.

²Institute of Medical Sciences, Faculty of Medicine, University of Liverpool, Liverpool, UK.

³Department of Transplantation, Liverpool University Teaching Hospitals NHS Foundation Trust, Liverpool, UK.


⁴Renal Department, Doncaster Royal Infirmary, Doncaster, UK.

⁵Sheffield Kidney Institute, Sheffield Teaching Hospitals, Sheffield, UK.



Basiliximab and transplant outcome

- Acute rejection impairs graft survival
- Immunosuppressive protocols have been designed to overcome this challenge
- Basiliximab has been authorized as induction therapy since 2000



KDIGO Guidelines

1.2: We recommend including induction therapy with a biologic agent as part of the initial immunosuppressive regimen in KTRs. (1A)

1.2.1: We recommend that an IL2-RA be the first-line induction therapy. (1B)



Cyclosporine

Tacrolimus

Methodology

- **We conducted a systematic review in PubMed, Medline, Embase and Cochrane databases to identify studies and research work that assessed effect of basiliximab on renal transplant outcomes.**
- **Standard risk for renal transplant was defined as:**
 - **Less than 2 DR mismatch**
 - **Panel reactive antibody (PRA) less than 20%**
 - **Recipients with no more than one previous transplant**




Inclusion criteria

- **Studies that compared basiliximab to placebo or no induction therapies**
- **Standard risk population**
- **English language papers**

Exclusion criteria

- **Level 3-5 of evidence**
- **Studies that compared basiliximab to other depleting or non-depleting antibodies induction therapies**
- **Cyclosporine-based immunotherapy**
- **High risk renal transplant recipients**
- **Follow-up period less than 1 year**
- **Studies performed on animals**
- **Dual organ transplant**
- **Organ transplant other than the kidneys**



Excluded 81 repetitions

379 excluded:

- 271 unrelated
- 34 basiliximab versus ATG
- 26 Cyclosporine in he CNI
- 26 review articles
- 6 basilximab vs. daclizumab

3 papers excluded for short follow-up



Results


Author	Type of study	Country	Journal	Year
Wiland et al	Retrospective observational study	USA	Transplantation	2004
Gralla et al	Retrospective observational study	USA	Transplantation	2010
Sandes-Frietas et al	Retrospective observational study	Brazil	International nephrology	2013
Schwarz et al	Retrospective observational study	Austria	Transplantation proceedings	2015
Umber et al	Retrospective observational study	Italy	Journal of nephrology	2017
Martinez et al	Retrospective observational study	Spain	Transplantation proceedings	2009
Baek et al	Prospective study	Korea	Experimental transplantation	2016



Baseline characteristics	Basiliximab group (n=14974)	No basiliximab group(n=14667)	P value
Gender (male,%)	62.3%	62.9%	0.28
Recipient age (years, mean)	48.65	47.09	
Donor age (years, mean)	40.05	38.95	
Cold ischemia time (hours,mean)	19.3	16.1	
Number of extended criteria donors	1347	1388	0.16



Acute rejection rate



Graft survival

Study ID

RD (95%CI)

Wiland et al (2004)



0(-0.05,0.06)

Gralla et al (2010)



0(-0,0.01)

Sandes-Frietas et al (2013)



-0.02(-0.11,0.06)

Umber et al (2017)



-0.07(-0.16,0.02)

Martinez et al (2009)



0.07(-0.07,0.20)

Baek et al (2016)



0(-0.04,0.04)

Overall

(I-squared = 0.0%, p = 0.625)




0(0,0.01)

-0.204


0

0.204

Patient survival



Funnel plot with pseudo 95% confidence limits



Secondary results

- **Change in creatinine**
- **NODAT**
- **CMV**



Conclusions

- **Basliximab induction therapy has no significant effect on acute rejection rate, patient or graft survival in standard-risk renal transplant recipients with tacrolimus-based maintenance immunotherapy.**
- **More randomised-controlled studies are needed to address these.**



Acknowledgements

- Supervisors at Liverpool University

Dr. Ahmed Halawa

Dr. Ajay Sharma

Dr. Atif Mohiuddin

Dr. Mohsen El Kosi



- Library of Royal Wolverhampton hospitals

Tina Dangerfield

John Hudson

The Royal Wolverhampton 
NHS Trust

References

- Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR, Jr., et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. *Transplantation*. 2004;77(3):422-5.
- Gralla J, Wiseman AC. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. *Transplantation*. 2010;90(6):639-44.
- de Sandes-Freitas TV, Felipe CR, de Franco MF, Tedesco-Silva H, Medina-Pestana JO. Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens. *Int Urol Nephrol*. 2013;45(2):537-46
- Schwarz C, Bohmig G, Steininger R, Unger L, Kristo I, Kozakowski N, et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. *Transplant Proc*. 2015;47(8):2446-9.
- Umber A, Killackey M, Paramesh A, Liu Y, Qin H, Atiq M, et al. A comparison of three induction therapies on patients with delayed graft function after kidney transplantation. *J Nephrol*. 2017;30(2):289-95.
- Gavela Martinez E, Avila Bernabeu AI, Sancho Calabuig A, Beltran Catalan S, Escudero Quesada V, Pallardo Mateu LM. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression. *Transplant Proc*. 2009;41(6):2337-8.
- Hee Baek C, Hyun Kim J, Yu H, Shin E, Cho H, Kim H, et al. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea 2016



Thank you!

